• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Jensen Mark Edwin

    10/31/24 4:47:08 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ME alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Jensen Mark Edwin

    (Last) (First) (Middle)
    C/O 23ANDME HOLDING CO.
    223 N. MATHILDA AVE

    (Street)
    SUNNYVALE CA 94086

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/28/2024
    3. Issuer Name and Ticker or Trading Symbol
    23andMe Holding Co. [ ME ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit List: Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Mark Jensen by Guy Chayoun attorney-in-fact 10/31/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ME alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ME

    DatePrice TargetRatingAnalyst
    11/29/2022$7.00Buy
    Berenberg
    9/22/2022$6.00Outperform
    Cowen
    2/11/2022$14.00 → $11.00Outperform
    Credit Suisse
    12/20/2021$13.00 → $9.00Neutral
    Citigroup
    11/15/2021$12.00 → $13.00Buy → Neutral
    Citigroup
    11/11/2021$13.00 → $14.00Outperform
    Credit Suisse
    8/17/2021$13.00Outperform
    Credit Suisse
    7/12/2021$14.00Buy
    Citigroup
    More analyst ratings

    $ME
    Leadership Updates

    Live Leadership Updates

    See more
    • 23andMe Appoints Three New Independent Directors to Board

      SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

      10/29/24 7:30:00 AM ET
      $ANSS
      $CDLX
      $LSCC
      $ME
      Computer Software: Prepackaged Software
      Technology
      Computer Software: Programming Data Processing
      Semiconductors
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

      SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company. 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies. Furthermore, 23andMe hopes to help the pharmac

      5/8/23 7:00:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

      SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

      11/15/24 4:48:20 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

      SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

      11/15/24 4:20:24 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 23andMe Holding Co.

      SC 13G - 23andMe Holding Co. (0001804591) (Subject)

      11/13/24 6:00:29 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    SEC Filings

    See more
    • SEC Form 8-K filed by 23andMe Holding Co.

      8-K - 23andMe Holding Co. (0001804591) (Filer)

      3/28/25 4:09:11 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - 23andMe Holding Co. (0001804591) (Filer)

      3/24/25 6:23:28 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by 23andMe Holding Co.

      10-Q - 23andMe Holding Co. (0001804591) (Filer)

      2/6/25 4:27:52 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Kvarda Matthew

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      3/26/25 4:38:00 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Walper Thomas B.

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      3/26/25 4:35:46 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,654 shares, decreasing direct ownership by 6% to 96,468 units (SEC Form 4)

      4 - 23andMe Holding Co. (0001804591) (Issuer)

      2/21/25 5:05:56 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care